Beijing News (Reporter Zhang Zhaohui) On September 13, Science Sun announced that it had signed the "Capital Increase Agreement" with Baixi Ousi (Beijing) Biological Technology Co., Ltd., subscribing to the additional registered capital of RMB 481,500 for RMB 15 million. After the completion of this capital increase, Science Sun will hold 4.35% of Baixi Ousi's equity.
Previously, Science Sun, Baixi Ousi, and Wei Hui signed the "Equity Transfer Agreement" on May 17, 2021. Science Sun subscribed to Baixi Ousi's registered capital of RMB 307,550 for RMB 6 million, holding 2.35% of Baixi Ousi's equity.
Baixi Ousi (Beijing) Biological Technology Co., Ltd. is a national high-tech enterprise dedicated to the research, development, and translation of innovative drugs in the field of neurological diseases, with a focus on peptide drugs and large molecule drug development. BXOS110 is a self-developed peptide-based PSD-95 inhibitor by Baixi Ousi, used for emergency treatment of acute ischemic stroke within 24 hours of onset (PSD-95 inhibitors are the only non-thrombolytic stroke treatment drugs with a clear mechanism of action globally). BXOS110 is a novel, effective, and safe neuroprotective agent, with global patent layouts and has obtained 25 domestic and international invention patents. There are currently no similar products on the market; the only competitor targeting the same point is NA-1 from Canada’s NoNO Inc. In preclinical studies, BXOS110 demonstrated superior efficacy and safety compared to NA-1. The drug is currently undergoing Phase II clinical trials, and once approved, BXOS110 will become the first PSD-95 inhibitor in China and the second globally.
Proofread by Liu Jun